Drug Type Chemical drugs |
Synonyms |
Target |
Mechanism KDM3B inhibitors(lysine demethylase 3B inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Rhabdomyosarcoma | Preclinical | US | 15 Apr 2024 | |
Rhabdomyosarcoma | Preclinical | US | 15 Apr 2024 |